2019 New Idea Awards

The New Idea Award recognizes researchers who are investigating potentially transformative ideas to significantly improve clinical outcomes for patients with blood cancers. These research projects may eventually lead to significant improvements in the clinical outcomes of patients with hematological malignancies.

Donate Today


 

New Idea Awardees

Dr. Cheryl Arrowsmith

Dr. Cheryl Arrowsmith

University Health Network
Toronto, Ontario​ Co-applicant: Dr. Mark Minden Targeting repressive chromatin complex mutations in acute myeloid leukemia PRC2 is a multi-protein complex that controls the genes important for normal blood cell development and leukemia progression. Mutations in the genes encoding the components of PRC2 are found in myelodysplasia, myeloproliferative disorders and Acute Myel...

Dr. Goetz Ehrhardt

Dr. Goetz Ehrhardt

The University of Toronto
Toronto, Ontario​ Therapeutic potential of variable lymphocyte receptor antibodies Conventional antibodies play an increasingly important role in cancer therapy because of their ability to bind to target cells with very high specificity. However, it remains a great challenge to identify targets that are uniquely expressed on cancer cells so as to avoid damage to non-cancer cel...

Dr. Trang Hoang

Dr. Trang Hoang

Université de Montréal
Montréal, Québec Co-applicants: Dr. Claude Perreault, Dr. Pierre Thibault Uncovering tumor specific antigens in ETP acute lymphoblastic leukemia Early T-cell Precursor Acute lymphoblastic leukemia subtype (ETP-ALL) is associated with resistance to chemotherapy and poor prognosis, especially in adults. Stem cell transplantation is beneficial in a large proportion of pati...

Dr. Robert Kridel

Dr. Robert Kridel

University Health Network
Toronto, Ontario​ A novel method to identify synergistic lethality in B-cell lymphoma Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive lymphoma subtype in which relapse after front-line treatment remains a major challenge. Such patients have very poor outcomes. Better therapeutic strategies are thus urgently needed to increase upfront cure rates. We propose to ...

Dr. Martin Petkovich

Dr. Martin Petkovich

Queen’s University
Kingston, Ontario​ Co-applicant: Dr. Michael Rauh Small molecule targeting of CYP26B1 in myeloid leukaemia Retinoic Acid (RA) has been used since the 1980s to treat certain types of blood cancers. AML is a blood cancer characterized by the growth and accumulation of immature cells, known as blasts, in the bone marrow and blood. RA is able to change the blast cells that cause can...